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Drs. Jenkins and Glenn raise an interesting point about the
statistical powering and evaluation of the study. It should be
realized that the study was designed as a so-called proof-of-
concept study exploring the potential effect of miglustat in
the treatment of cystic fibrosis. In such a go/no go study,
which is usually decisive for the further fate of the drug in the
indication tested, a clinically relevant endpoint should be
defined on the basis of which the sample size will be
determined. A proof-of-concept study is normally performed
in a homogeneous patient population, at a relatively high dose
(to give the drug optimal chances of success), and under
standardized conditions. Therefore, also a crossover design
was selected in which each patient functions as his or her own
control. A sample size of 11 patients was calculated, needed
to demonstrate with 90% power a difference of 5.0 mV in
total chloride secretion between placebo and miglustat,
assuming a standard deviation of the differences between
two repeated assessments on the same patient of 4.4 mV [1],
using a paired t-test with a 0.05 two-sided significance level.
A difference of 5.0 mV was chosen as the effect size to be
detected as it is considered to be clinically relevant [2,3]. The
study results were in accordance with the null hypothesis, i.e.,
of no difference between the effects of miglustat and placebo
on the NPD endpoint. Obviously, it cannot be excluded that
the treatment had some effect on the endpoint but this raises
the question whether a smaller effect size can still be
considered clinically relevant. Since the study was not
powered to detect a smaller effect size, only a study with
larger patient numbers would be able to detect unequivocally
such effect.
The duration of treatment of 8 days was not only justified by
the establishment of steady-state pharmacokinetic conditions of
miglustat within a few days (due to its relatively short half-life),
but also by the fact that the half-life of the CFTR protein in the
plasma membrane is short (b24 h) [4]. This means that full
effects of the drug, if any, should certainly be developed within
8 days of treatment. The pharmacodynamics of the drug are1569-1993/$ -see front matter © 2012 European Cystic Fibrosis Society. Published
doi:10.1016/j.jcf.2012.06.004quickly translated in changes in NPD, which cannot be
compared to the situation with antidepressants as suggested
by Drs. Jenkins and Glenn.
In a model of respiratory CF cells chronically treated with
low-concentration miglustat, rescue of F508del-CFTR function
was maximal and then stable after 4 days of treatment while
disappearing within 4 days after washing out the drug [5].References
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